VLVeli-Pekka Lehto

Veli-Pekka Lehto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Veli-Pekka Lehto has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Olli Lohi

    Tampere Center for Child, Adolescent, and Maternal Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

    2 shared publications
  • Anssi M. Poussu

    Department of Pathology, University of Oulu, PO Box 5000 (Aapistie 5), Oulu FIN-90410, Finland

    1 shared publication
  • Auli Linnala

    † From the Department of Anatomy, University of Helsinki, Helsinki, Finland

    1 shared publication
  • Dia Kamel

    From the Department of Pathology, University of Oulu, Oulu

    1 shared publication
  • Ismo Virtanen

    † From the Department of Anatomy, University of Helsinki, Helsinki, Finland

    1 shared publication
  • Jari Meriläinen

    Biocenter Oulu and the Department of Pathology, University of Oulu, FIN-90220 Oulu, Finland

    1 shared publication

Latest Publications

  • EGF receptor: which way to go?

    by Veli-Pekka Lehto


  • Vear, a novel Golgi-associated protein, is preferentially expressed in type I cells in skeletal muscle

    by Anssi M. Poussu, Philip H. Thompson, Veli-Pekka Lehto, Markus J. Mäkinen

    Vear is a novel Golgi‐associated protein with a domain structure characteristic of many vesicular transport–associated proteins. It has been suggested that Vear is involved in vesicle transport through trans‐Golgi. In this study, we have determined the localization of Vear in skeletal muscle. The staining for Vear in normal human muscle revealed a distribution pattern similar to that of type I fibers. We conclude that Vear is preferentially expressed in type I fibers in human muscle, presumably indicative of a specific function that remains to be identified. © 2001 John Wiley & Sons, Inc. Muscle Nerve 24: 127–129, 2001.


  • Open Access

    EAST, a novel EGF receptor substrate, associates with focal adhesions and actin fibers

    by Olli Lohi, Veli-Pekka Lehto

    EAST is a novel epidermal growth factor receptor (EGFR) substrate. It interacts with Eps15, another EGFR substrate which is involved in receptor endocytosis. In this study we show that EAST associates with focal adhesions and actin filaments. First, in immunofluorescence and electron microscopy analysis, an extensive codistribution of EAST with vinculin, paxillin and actin filaments was seen. Second, overexpression of the NH2 terminus of EAST led to a formation of actin‐rich microspikes and membrane protrusions. Third, in cosedimentation assay EAST showed a direct association with actin. These results suggest that EAST is involved in the EGFR‐regulated reorganization of the actin cytoskeleton and may be part of a link between cytoskeleton and endocytic machinery.


  • Open Access

    Src phosphorylates EAST, a novel EGF receptor‐associated protein

    by Olli Lohi, Veli-Pekka Lehto

    We have recently found and characterized EAST, a novel EGF receptor‐associated protein with SH3 and TAM domains. In this study we show that EAST becomes phosphorylated by Src kinase. This, in conjunction with our earlier observations on the close association between EAST and the endocytic machinery, suggests that EAST could be involved in Src‐dependent effects on EGF receptor endocytosis.


  • Open Access

    FAP52, a Novel, SH3 Domain-containing Focal Adhesion Protein

    by Jari Meriläinen, Veli-Pekka Lehto, Veli-Matti Wasenius


  • Open Access

    Tenascin Immunoreactivity in Lung Tumors

    by Ylermi Soini, Paavo Pääkkö, Kyösti Nuorva, Dia Kamel, Auli Linnala, Ismo Virtanen, Veli-Pekka Lehto

    The distribution of tenascin immunoreactivity was analyzed in nonneoplastic lung tissue, benign lung tumors, and different types of lung carcinomas. In nonneoplastic lung tissue, tenascin could be observed in the basement membranes of the bronchial epithelium and endothelial cells, smooth muscle cells, and bronchial cartilage. Strong tenascin immunoreactivity was seen in the stroma of all the carcinomas of various histologic types. The staining intensity was stronger in the stroma of squamous cell carcinomas than in the stroma of the other types of lung carcinomas. In 10 of 27 squamous cell carcinomas, a granular intracytoplasmic reactivity could also be observed in a subpopulation of tumor cells. Similar intracytoplasmic reactivity was observed in 2 of 27 adenocarcinomas and in both adenosquamous carcinomas. In other types of lung tumors, individual cells did not have intracytoplasmic tenascin, except for one case of leiomyoma, which showed a weak, linear, intracytoplasmic tenascin reactivity. In lung hamartomas, tenascin could be seen in the cartilaginous component of the tumor and in the areas of basement membranes of the bronchial epithelium. In the carcinoid tumors, the stroma displayed a faint positivity for tenascin. These results show that tenascin is widely expressed in the stroma of lung carcinomas. A proportion of lung carcinomas also expressed intracytoplasmic tenascin immunoreactivity, suggesting that tumor cells may be able to synthesize tenascin. In the lung, tenascin positivity is not, however, restricted to malignant neoplasms, as evidenced by the presence of tenascin in nonneoplastic lung parenchyma and in some benign lung tumors.